Can keto/amino acids reduce oxidative stress in peritoneal dialysis patients with hypoalbuminemia?. Issue 5 (1st April 2021)

• Record Type: Journal Article
• Authors: Çankaya, Erdem; Bilen, Yusuf; Uyanık, Abdullah; Dogan, Hasan; Kızıltunç, Ahmet; Sevinç, Can
• Is Part Of: Seminars in dialysis. Volume 34:Issue 5(2021)
• Page Start: 375
• Page End: 379
• Publication Date: 2021-04-01
• Subjects: arylesterase -- malondialdehyde -- oxidative stress -- paraoxonase‐1 -- peritoneal dialysis -- sialic acid; Hemodialysis -- Periodicals; Dialysis -- Periodicals; Renal Dialysis -- Periodicals; 617.461059
• DOI: 10.1111/sdi.12971
• Languages: English
• ISSNs: 0894-0959

Abstract

Abstract: Introduction: There is no consensus on an ideal marker of oxidative stress (OS). Disruption of the balance between free radical and antioxidant activity production by increasing oxidative markers results in OS. In this study, we aimed to investigate how OS, which increases mortality and morbidity due to various reasons, is affected by keto/amino therapy in patients with hypoalbuminemia undergoing peritoneal dialysis. Materials and Method: Twenty patients who underwent peritoneal dialysis were included in the study. Before starting keto/amino acid therapy, primary kidney diseases were determined, body mass indexes, serum total protein, albumin, C‐reactive protein, ferritin, calcium, phosphorus, parathyroid hormone, paraoxonase‐1 (PON‐1), sialic acid levels, arylesterase (ARE) activities, and malondialdehyde (MDA) levels were measured, and Kt/V values were calculated. Keto/amino acid treatment was initiated for those with an albumin level of <3.5 g/dL. The same parameters of the patients, followed up for 3 months, were checked again at the end of the third month. Results: Paraoxonase‐1 and ARE activities, which are antioxidant enzyme activities, were found to be statistically significantly increased compared to the initial period (59 ± 59, 135 ± 69, 15.8 ± 19.7, and 44.7 ± 16.4, respectively; p < 0.00). MDA and sialic acid levels were significantly lower than the initial values (109 ± 99, 23 ± 9, 2.26 ± 0.44, and 2.04 ± 0.39, respectively; p < 0.01). Conclusion: In our study, after the initiation of keto/amino acid treatment, PON‐1, which is a significant antioxidant marker, and ARE plasma activities increased and tissue destruction product MDA and sialic acid significantly decreased. In the light of all these data, we think that this treatment can reduce OS, improve hypoalbuminemia, which causes both mortality and morbidity in patients, improve survival in PD patients, and may be an antioxidant treatment in suitable patients.